Skip to main content

ZymoGenetics announces launch of biosurgery unit headed by former Bayer leader


SEATTLE ZymoGenetics plans to form a biosurgery business unit focused on the topical drug Recothrom Thrombin. It has hired Stephen Zaruby to head the division and serve as president of the company starting Jan. 2.

“Recothrom is an important asset with the potential to generate significant value, which we believe will best be realized by having a focused business unit,” ZymoGenetics CEO and board chairman Bruce Carter said in a statement. “With the addition of Stephen Zaruby and his proven expertise in building markets for hospital products, we?ve strengthened our management team overall and ofund the right person to lead our biosurgery business unit and build it into a valuable business.”

Previously, Zaruby served as VP and global head of the hospital and surgical business unit for hematology and cardiology for Bayer HealthCare Pharmaceuticals. At Bayer, he was the global strategic and United States operational head for hospital, surgical and related specialty products.

This ad will auto-close in 10 seconds